Performance of Copy Number Variant Detection from Short-Read Whole Genome Sequencing for Clinical Gene-Panel Applications

Francisco M. De La Vega,¹ Sean A. Irvine,² Pavana Anur,¹ Kelly Potts,¹ Lewis Kraft,¹ Raul Torres,¹ Sean Truong,³ Yeonghun Lee,³ Shunhua Han,³ Vitor Onuchic,³ James Han,³ and Peter Kang¹

¹Tempus Labs, Chicago, IL, USA. ²Real Time Genomics, Ltd., Hamilton, New Zealand, and ³Illumina, Inc., San Diego, CA, USA

INTRODUCTION

Whole Genome Sequencing (WGS) will soon be preferred over Whole Exome Sequencing (WES) and targeted sequencing in clinical settings due to its better CNV/SV detection, faster

turnaround time, and dropping costs. Current tools for short-read WGS CNV calling need to be evaluated for clinical settings where orthogonal confirmation of CNVs may be required, placing a higher priority on sensitivity over

specificity/precision compared to research uses. We aimed to evaluate CNV detection tools designed for short-read, PCR-free WGS data using cell lines with known CNVs, to determine their potential for clinical gene-panel reporting at 50X WGS coverage.

METHODS

CNV calling tools evaluated

• Delly (v1.6), CNVpytor (v1.3), Cue (cue.v2.pt model), and the new DRAGEN 4.2 CNV caller that combines depth and breakpoint calls.

Data Sources

- We selected 33 cell lines from the Coriell Institute catalogue with reported CNVs overlapping genes a panel comprised of 89 hereditary cancer genes, 79 cardiometabolic disease, and 20 rare genetic disease genes
- WGS PCR-free libraries were sequenced to a mean depth of 50X using paired-end 2x150bp reads on the Illumina NovaSeq 6000.
- Reads were mapped to the GRCh37 human reference with the DRAGEN mapper.

Benchmarking analyses

- As truth set, we used annotations for the cell lines described on the Coriell Institute website.
- We centered our evaluation on proteinstructure disrupting CNVs due to our clinical application, rather than on the accuracy of breakpoint location.
- We thus counted events intersecting an exon when the dosage direction matched the truth set as true positives. Events not meeting this condition were considered false positives. We made adjustments for events spanning multiple exons to avoid double counting.

SUMMARY

- lacksquare

RESULTS

Table 1. List of cell lines with expected CNVs

Coriell ID	Gene(s) affected	Chr	Length (kb)	# of exons	Туре
HG00343	CHEK2	22	5	2	DEL
HG00634	PALB2	16	13	1	DUP
HG03694	ATM	11	16	4	DUP
NA02325	AXIN1-MEFV-PKD1-TSC2	16	>3,000	145	DUP
NA02325	LZTR1-SMARCB1-CHEK2-NF2	22	>5,500	60	DUP
NA03330	PARK2	6	198	1	DUP
NA03330	BRCA2-N4BP2L1	13	3,174	26	DUP
NA03330	SUCLA2	13	1,924	38	DUP
NA03330	PARK2	6	198	1	DUP
NA04372	GALC	14	32	7	DEL
NA04517	GALC	14	32	7	DEL*
NA04520	TSC2	16	89	35	DEL
NA05117	DMD	Х	165	2	DEL
NA08618	ATM-DDX10	11	>3,500	125	DUP
NA10283	DMD	Х	358	16	DEL*
NA11661	GAA	17	1	1	DEL
NA13434	PLP1	Х	1	2	DEL*
NA13480	ELN	7	1,304	33	DUP
NA13480	JAK2	9	133	3	DUP
NA14626	BRCA1	17	6	1	DUP
NA18668	CFTR	7	21	2	DEL
NA18949	BRCA1	17	6	2	DEL
NA19401	TK2	16	6	1	DEL
NA20381	CLN3	16	1	2	DEL
NA21698	PARK2-PACRG	6	>4,500	1	DEL
NA21939	FBN1	15	6	4	DEL
NA22208	PCCA	13	147	8	DEL
NA23599	MECP2	Х	15	2	DEL
NA23710	CDKL5	Х	8	2	DEL
ND01039	PARK2	6	156	1	DEL

Table 1: Cell lines sequenced in this study. The table indicates the gene(s) overlapped by a CNV, chromosome (chr), length of relevant events (based on our calls with DRAGEN), number of exons overlapped by CNV, and the type of event, either deletion (DEL) or duplication (DUP). * indicates homozygous. Some of these cell lines have multiple events and large complex rearrangements not listed by Coriell. We examined likely true positives, and when deemed confident, we added them to the truth set.

We also included seven cell lines in the study (not in the table) that harbor CNV events where a targeted caller is required due to extensive paralogy (e.g., CYP2D6, GBA, and PMS2). In this study, we excluded calls across these genes from our evaluation and treated these cell lines as "true negatives" for the assessment of the false positive rate per sample.

Our benchmarking of CNV callers using cell line WGS data showed that DRAGEN v4.2 provides the best balance between sensitivity and precision, with a high sensitivity mode (HS) that trades precision for peak sensitivity. • Custom filters that remove recurrent artifacts and breakpoints in problematic regions decrease the false positives of DRAGEN HS without affecting its sensitivity, making it suitable for clinical settings that require confirmatory tests.



Fig. 2: Coverage graphs (100bp bins) indicating DRAGEN CNV calls (lines with arrow heads); "D" indicates that call is backed by depth analysis, and "J" indicates that call is backed by junction reads (breakpoints). Shaded green vertical areas represent exons of the canonical transcript of genes in the panel, while others are shown in blue. **Panel A** - true positive (TP) DEL in FBN1; **Panel B** - TP DUP in PARK2; **Panel C** - false positive (FP) DEL in the PMS2 gene, due to mappability issues in paralogous regions to the *PMS2CL* pseudogene (drop of mapq>5 coverage line); **Panel D** – a TP DEL in ACTN2 where the overextended right breakpoint in the call results in a FP exon overlap.

TEMPUS